Katherine E Fleming-Dutra
Overview
Explore the profile of Katherine E Fleming-Dutra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
3535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiegand R, Devine O, Wallace M, Ortega-Sanchez I, Pham H, Khan D, et al.
Vaccine
. 2025 Jan;
49:126808.
PMID: 39889531
COVID-19-associated hospitalizations, ICU admissions, and in-hospital deaths averted from 2023 to 2024 COVID-19 vaccination from the weeks of October 1, 2023, through April 21, 2024, were estimated via a novel...
2.
Roper L, Link-Gelles R, Surie D, DeCuir J, Zambrano L, Prill M, et al.
Vaccine
. 2025 Jan;
45():126633.
PMID: 39755055
During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV...
3.
Hutton D, Prosser L, Rose A, Mercon K, Ortega-Sanchez I, Leidner A, et al.
Pediatrics
. 2024 Nov;
154(6).
PMID: 39582316
Background And Objectives: Respiratory syncytial virus (RSV) causes substantial hospitalization in US infants. The Advisory Committee on Immunization Practices recommended nirsevimab in infants younger than 8 months born during or...
4.
Hutton D, Prosser L, Rose A, Mercon K, Ortega-Sanchez I, Leidner A, et al.
Pediatrics
. 2024 Nov;
154(6).
PMID: 39582303
Background And Objectives: Respiratory syncytial virus (RSV) commonly causes hospitalization among US infants. A maternal vaccine preventing RSV in infants, RSV bivalent prefusion F maternal vaccine (RSVpreF), was approved by...
5.
Ciesla A, Mak J, Roper L, Fleming-Dutra K, Smith Z, Wiegand R, et al.
Influenza Other Respir Viruses
. 2024 Nov;
18(11):e70038.
PMID: 39522959
Background: On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance. Methods: Using national pharmacy-based SARS-CoV-2 testing...
6.
Payne A, Watts J, Mitchell P, Dascomb K, Irving S, Klein N, et al.
Lancet
. 2024 Oct;
404(10462):1547-1559.
PMID: 39426837
Background: Respiratory syncytial virus vaccines first recommended for use during 2023 were efficacious against lower respiratory tract disease in clinical trials. Limited real-world data regarding respiratory syncytial virus vaccine effectiveness...
7.
Panagiotakopoulos L, Moulia D, Godfrey M, Link-Gelles R, Roper L, Havers F, et al.
MMWR Morb Mortal Wkly Rep
. 2024 Sep;
73(37):819-824.
PMID: 39298394
COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States for...
8.
Ciesla A, Lazariu V, Dascomb K, Irving S, Dixon B, Gaglani M, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae481.
PMID: 39286032
Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023-2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people,...
9.
Britton A, Roper L, Kotton C, Hutton D, Fleming-Dutra K, Godfrey M, et al.
MMWR Morb Mortal Wkly Rep
. 2024 Aug;
73(32):696-702.
PMID: 39146277
Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization in older adults during fall and winter in the United States. The 2023-2024 RSV season was the...
10.
Moro P, Scheffey A, Gallego R, Jones J, Hall E, Zhang B, et al.
Pediatrics
. 2024 May;
153(6).
PMID: 38721658
No abstract available.